646 related articles for article (PubMed ID: 19658448)
21. The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome.
Kim DH; Yoon KC; Seo KY; Lee HS; Yoon SC; Sotozono C; Ueta M; Kim MK
Ophthalmology; 2015 Feb; 122(2):254-64. PubMed ID: 25262319
[TBL] [Abstract][Full Text] [Related]
22. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome.
Hebert AA; Bogle MA
J Am Acad Dermatol; 2004 Feb; 50(2):286-8. PubMed ID: 14726889
[TBL] [Abstract][Full Text] [Related]
23. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin: a series of three cases.
Comparin C; Hans Filho G; Takita LC; Costa Nde C; Nascimento RA; Nanni Lde O
An Bras Dermatol; 2012; 87(3):477-81. PubMed ID: 22714769
[TBL] [Abstract][Full Text] [Related]
24. Drug eruption due to peplomycin: an unusual form of Stevens-Johnson syndrome with pustules.
Umebayashi Y; Enomoto H; Ogasawara M
J Dermatol; 2004 Oct; 31(10):802-5. PubMed ID: 15672707
[TBL] [Abstract][Full Text] [Related]
25. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome.
Mittmann N; Chan B; Knowles S; Cosentino L; Shear N
Am J Clin Dermatol; 2006; 7(6):359-68. PubMed ID: 17173470
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 May; 41(5):812-23. PubMed ID: 17440006
[TBL] [Abstract][Full Text] [Related]
27. Plasmapheresis as adjuvant therapy in Stevens-Johnson syndrome and hepatic encephalopathy.
Hung PC; Wang HS; Hsia SH; Wong AM
Brain Dev; 2014 Apr; 36(4):356-8. PubMed ID: 23777679
[TBL] [Abstract][Full Text] [Related]
28. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies.
Barron SJ; Del Vecchio MT; Aronoff SC
Int J Dermatol; 2015 Jan; 54(1):108-15. PubMed ID: 24697283
[TBL] [Abstract][Full Text] [Related]
29. Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses.
Michael D; Grando SA
Curr Dir Autoimmun; 2008; 10():333-43. PubMed ID: 18460894
[TBL] [Abstract][Full Text] [Related]
30. Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature.
Metry DW; Jung P; Levy ML
Pediatrics; 2003 Dec; 112(6 Pt 1):1430-6. PubMed ID: 14654625
[TBL] [Abstract][Full Text] [Related]
31. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome.
Fromowitz JS; Ramos-Caro FA; Flowers FP;
Int J Dermatol; 2007 Oct; 46(10):1092-4. PubMed ID: 17910723
[TBL] [Abstract][Full Text] [Related]
32. Drug-induced linear IgA bullous dermatosis mimicking toxic epidermal necrolysis.
Hughes AP; Callen JP
Dermatology; 2001; 202(2):138-9. PubMed ID: 11306837
[No Abstract] [Full Text] [Related]
33. The use of intravenous immunoglobulin in autoimmune bullous diseases.
Chee SN; Murrell DF
Dermatol Clin; 2011 Oct; 29(4):565-70. PubMed ID: 21924999
[TBL] [Abstract][Full Text] [Related]
34. Clinical resemblance of widespread bullous fixed drug eruption to Stevens-Johnson syndrome or toxic epidermal necrolysis: report of two cases.
Lin TK; Hsu MM; Lee JY
J Formos Med Assoc; 2002 Aug; 101(8):572-6. PubMed ID: 12440088
[TBL] [Abstract][Full Text] [Related]
35. Stevens Johnson syndrome in association with Mycoplasma pneumonia.
Manwani NS; Balasubramanian S; Dhanalakshmi K; Sumanth A
Indian J Pediatr; 2012 Aug; 79(8):1097-9. PubMed ID: 22012144
[TBL] [Abstract][Full Text] [Related]
36. [Analysis of treatments and deceased cases of severe adverse drug reactions--analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis].
Yamane Y; Aihara M; Tatewaki S; Matsukura S; Kanbara T; Yamakawa Y; Ikezawa Z
Arerugi; 2009 May; 58(5):537-47. PubMed ID: 19487835
[TBL] [Abstract][Full Text] [Related]
37. Vesicular and bullous eczema in response to intravenous immunoglobulins (IVIG).
Maetzke J; Sperfeld AD; Scharffetter-Kochanek K; Sunderkötter C
Allergy; 2006 Jan; 61(1):145-6. PubMed ID: 16364173
[No Abstract] [Full Text] [Related]
38. Fixed drug eruptions, bullous drug eruptions, and lichenoid drug eruptions.
Cheraghlou S; Levy LL
Clin Dermatol; 2020; 38(6):679-692. PubMed ID: 33341201
[TBL] [Abstract][Full Text] [Related]
39. [Unintended rechallenge : Generalized bullous fixed drug eruption in two elderly women].
Paulmann M; Mockenhaupt M
Hautarzt; 2017 Jan; 68(1):59-63. PubMed ID: 27448063
[TBL] [Abstract][Full Text] [Related]
40. [Stevens-Johnson syndrome plus intrahepatic cholestasis caused by clindamycin or chlorpheniramine].
Sahagún Flores JE; Soto Ortiz JA; Tovar Méndez CE; Cárdenas Ochoa EC; Hernández Flores G
Dermatol Online J; 2009 May; 15(5):12. PubMed ID: 19624990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
